IMPROVE-AD
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The primary objective of the IMPROVE-AD trial is to
determine whether an upfront invasive strategy of TEVAR
plus medical therapy reduces the occurrence of a composite
endpoint of all-cause death or major aortic complications
compared to an upfront conservative strategy of medical
therapy with surveillance for deterioration in patients with
uncomplicated type B aortic dissection followed for up to six
years with a primary assessment at four years.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855250
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
